A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
|Articles|November 19, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
The Outlook for Immunotherapies
Author(s)Julie R. Brahmer, MD
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.
Advertisement
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.
Learn more aboutimmunotherapies in cancer
Articles in this issue
almost 13 years ago
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanomaalmost 13 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersalmost 13 years ago
Immunotherapy—An Increasingly Important Role in Oncologyalmost 13 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyalmost 13 years ago
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhDalmost 13 years ago
PD-1 and PD-L1 Antibodies in Lung Canceralmost 13 years ago
Checkpoint Inhibitors in Cancer Carealmost 13 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadealmost 13 years ago
Nivolumab Plus Ipilimumab in Advanced MelanomaAdvertisement
Related to this article
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5